公开(公告)号：US20180147286A1

公开(公告)日：2018-05-31

申请号：US15578226

申请日：2016-05-29

Applicant: Jindrich Kopecek ,  Jiyan Yang ,  Purdue Research Foundation Office of Technology Commercialization ,  University of Utah Research Foundation

Inventor： Stewart Andrew Low ,  Philip S. Low ,  Christopher Galliford ,  Jindrich Kopecek ,  Jiyan Yang

IPC: A61K47/42 ,  A61M5/00 ,  A61P19/00 ,  A61K9/107 ,  A61K31/404

CPC classification number: A61K47/42 ,  A61K9/1075 ,  A61K31/404 ,  A61L27/22 ,  A61L27/227 ,  A61L27/54 ,  A61L2400/06 ,  A61L2430/02 ,  A61M5/002 ,  A61P19/00 ,  C07K7/06 ,  C07K7/08

Abstract: Aspects of the present disclosure generally relate to compounds for targeting and healing bone fractures. Some of these compounds include a negatively charged oligopeptide comprising an acidic oligopeptide, a linker, which may be hydrolyzable or may be a substrate for the protease cathepsin K, and at least one molecule that promotes bone healing. In some compounds the molecule that promotes bone healing is an anabolic compound that inhibits GSK3β, in some compounds the molecule that promotes the healing of bone fracture is a pro-inflammatory agent such as PGE1. Other embodiments include methods of treating a bone fracture comprising administering a therapeutic amount of any one of the compounds disclosed herein.

公开(公告)号：EP3185922A1

公开(公告)日：2017-07-05

申请号：EP15835953.9

申请日：2015-08-27

Applicant: Purdue Research Foundation Office of Technology Commercialization

Inventor： VOYTIK-HARBIN, Sherry

IPC: A61L31/04

CPC classification number: A61L27/24 ,  A61K9/0024 ,  A61K9/19 ,  A61K38/18 ,  A61K47/42 ,  A61L27/54 ,  A61L2300/414 ,  A61L2300/604 ,  A61L2400/06

Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent. Methods of making and using the pre-matrix composition and the device are also provided.

Abstract translation: 基于胶原的治疗递送装置包括不溶性合成胶原 - 原纤维基质，其包含可溶低聚胶原的聚合产物或可溶低聚胶原与一种或多种非寡聚可溶性胶原分子的混合物的聚合产物， 例如，可溶性端粒胶原和/或可溶性整链端胶原，以及分散在整个胶原 - 原纤维基质中或部分胶原 - 原纤维基质内的活性剂。 预基质组合物包括含有可溶性胶原 - 原纤结构单元和水溶液中的活性剂的水溶液。 可溶性胶原 - 原纤结构单元包括可溶性低聚胶原或可溶低聚胶原与非寡聚可溶性胶原分子的混合物。 在不存在外源交联剂的情况下，构建块可操作以自组装成大分子合成胶原 - 原纤维基质。 还提供了制造和使用预制基质组合物和装置的方法。